Exact Sciences

EXAS

Market cap $11.5B

After a stellar Q3 for Wall Street, five growth picks - MU, WDAY, EXAS, EVR, and CDE - stand out with rising earnings estimates.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2025 financial results after the close of the U.S. financial markets on November 3, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2025 webcast & conference call details Date: M.

Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of “Comparing Benefit-to-Burden Ratios of Endorsed and Emerging Colorectal Cancer Screening Strategies” in the Journal of the National Cancer Institute.1 The modeling study found that Cologuard Plus™, a triennial next-generation multitarget stool DNA (mt-sDNA) test, was the only noninvasive screening option shown to be efficient at guid.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exact Sciences (EXAS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EXAS crossed above the 20-day moving average, suggesting a short-term bullish trend.

Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver strong revenue growth, while Cancerguard expands its addressable market into multi-cancer early detection. Risks include regulatory hurdles, payer coverage, and competition from Guardant and Grail, but EXAS's brand and pipeline reinforce resilience.